Who are Secukinumab 150 milligram [Cosentyx]'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Taltz, Cosentyx, Vunakizumab (IL-17A inhibitor), Secukinumab Auto-Injector, Subcutaneous injection of Secukinumab, Proactive TDM-based dosing of ixekizumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/secukinumab-150-milligram-cosentyx.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Secukinumab 150 milligram [Cosentyx] — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Secukinumab 150 milligram [Cosentyx] (Secukinumab 150 milligram [Cosentyx]) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-17A inhibitor (monoclonal antibody). Area: Immunology.

marketed IL-17A inhibitor (monoclonal antibody) IL-17A Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Secukinumab 150 milligram [Cosentyx] (Secukinumab 150 milligram [Cosentyx]) — Professor Mikkel Østergaard. Secukinumab is a monoclonal antibody that blocks interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated diseases.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Secukinumab 150 milligram [Cosentyx] TARGET	Secukinumab 150 milligram [Cosentyx]	Professor Mikkel Østergaard	marketed	IL-17A inhibitor (monoclonal antibody)	IL-17A
Taltz	ixekizumab	Eli Lilly	marketed	Interleukin-17A antagonist	Interleukin 17A (IL-17A) cytokine	2016-01-01
Cosentyx	secukinumab	Novartis	marketed	IL-17A antagonist	Interleukin-17A (IL-17A)	2015-01-01
Vunakizumab (IL-17A inhibitor)	Vunakizumab (IL-17A inhibitor)	Fujian Cancer Hospital	marketed	IL-17A inhibitor (monoclonal antibody)	IL-17A
Secukinumab Auto-Injector	Secukinumab Auto-Injector	University of Pennsylvania	marketed	IL-17A inhibitor (monoclonal antibody)	IL-17A
Subcutaneous injection of Secukinumab	Subcutaneous injection of Secukinumab	Peking Union Medical College	marketed	IL-17A inhibitor (monoclonal antibody)	IL-17A (Interleukin-17A)
Proactive TDM-based dosing of ixekizumab	Proactive TDM-based dosing of ixekizumab	University Hospital, Ghent	marketed	IL-17A inhibitor; monoclonal antibody	IL-17A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-17A inhibitor (monoclonal antibody) class)

Eli Lilly and Company · 2 drugs in this class
Celltrion · 1 drug in this class
Biocad · 1 drug in this class
Peking Union Medical College · 1 drug in this class
Professor Mikkel Østergaard · 1 drug in this class
University of Pennsylvania · 1 drug in this class
Fujian Cancer Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Secukinumab 150 milligram [Cosentyx] — Competitive Intelligence Brief. https://druglandscape.com/ci/secukinumab-150-milligram-cosentyx. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab